Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024.

Looking ahead, revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 6.7% growth forecast ...

Acadia Realty Trust (NYSE:AKR – Free Report) by 10.0% during the 3rd quarter, Holdings Channel reports. The firm owned 21,535 ...

Acadia , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $250.4 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 0.46% ...

More defined timelines will be given in early 2025, probably with fourth quarter results or soon thereafter. In addition, ...

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the third quarter and nine months ended September 30, 2024. Third ...

These 10 defensive stocks supply investors with reliable earnings, and often dividends, when markets look uncertain. We sell different types of products and services to both investment ...

Good day, and welcome to Acadia Healthcare's Third Quarter of 2024 Earnings Call. All participants will be in a listen-only mode for the duration of the call. [Operator Instructions] After today’s ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20241106212607/en/ Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858) 261 ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported third-quarter net income of $32.8 million, after reporting a loss in the same period a year earlier. On a per ...

These non-GAAP financial measures include, and are defined, as follows: • EBITDA: net income (loss) attributable to Acadia Healthcare Company, Inc. adjusted for net income attributable to ...